Search research articles
Contact Us
Filters
Showing results (91-100 of 95) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 95 results.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia
|
February 29, 2012
Atopic dermatitis (AD) management in an Italian pediatric clinic
G Ruggiero, C Gelmetti, M C Adamo, et al.
Leukemia Research
|
February 1, 2015
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese"
G Mele, A Melpignano, G Quarta, et al.
Clinical and Experimental Medicine
|
November 25, 2025
A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide
I Rizzello, I Sacchetti, S Barbato, et al.
ESMO Open
|
March 12, 2026
Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape
F Gay, G Buda, M T Petrucci, et al.
ESMO Open
|
January 8, 2025
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients
E A Martino, S Palmieri, M Galli, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 95) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 95 results.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia
|
February 29, 2012
Atopic dermatitis (AD) management in an Italian pediatric clinic
G Ruggiero, C Gelmetti, M C Adamo, et al.
Leukemia Research
|
February 1, 2015
"Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese"
G Mele, A Melpignano, G Quarta, et al.
Clinical and Experimental Medicine
|
November 25, 2025
A multicenter observational retrospective study of second-line treatment with daratumumab-bortezomib-dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide
I Rizzello, I Sacchetti, S Barbato, et al.
ESMO Open
|
March 12, 2026
Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape
F Gay, G Buda, M T Petrucci, et al.
ESMO Open
|
January 8, 2025
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients
E A Martino, S Palmieri, M Galli, et al.
Page
of 10